In addition, SMAD4 loss in pancreatic cancer causes alterations to multiple kinase pathways (particularly the phosphorylated ERK/p38/Akt pathways), and increases chemoresistance in vitro15. Here, SMAD4 is linked to pancreatic neoplasm.